New natural history of interferon-β-treated relapsing multiple sclerosis-Reference-Cited by-同舟云学术

New natural history of interferon-β-treated relapsing multiple sclerosis

Published:2007-04 Issue:4 Volume:61 Page:300-306
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Trojano Maria,Pellegrini Fabio,Fuiani Aurora,Paolicelli Damiano,Zipoli Valentina,Zimatore Giovanni B.,Di Monte Elisabetta,Portaccio Emilio,Lepore Vito,Livrea Paolo,Amato Maria Pia

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference44 articles.

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial;The IFNB Multiple Sclerosis Study Group;Neurology,1993

2. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis;Jacobs;Ann Neurol,1996

3. Randomised double-blind placebo-controlled study of interferonb-1a in relapsing/remitting multiple sclerosis;PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group;Lancet,1998

4. PRISMS-4: long-term efficacy of interferonb-1a in relapsing MS;The PRISMS (Prevention of Relapses and Disability by Interferon-b-1a Subcutaneously in Multiple Sclerosis) Study Group;Neurology,2001

5. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial;The IFNB Multiple Sclerosis Study Group;Neurology,1995

Cited by 252 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity;Clinical Immunology;2024-10

2. Sclerosi multipla: aspetti evolutivi e prognostici;EMC - Neurologia;2024-08

3. Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis;Journal of Neuroimmunology;2024-07

4. Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study;The Lancet Regional Health - Americas;2024-01

5. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium;Journal of Neurology;2023-11-23